News
Celltrion USA today announced that STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo), biosimilars referencing PROLIA® ...
ReproNovo Announces First Participant Included in U.S. Phase 2 Trial of RPN-001 for Male Infertility
RPN-001 is a novel orally administered aromatase inhibitor being developed for the treatment of infertility in men with low serum testosteroneNo FDA-approved oral therapies currently exist for this un ...
The US subsidiary of South Korea-based Celltrion today announced that Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo) ...
Panelists discuss the SERENA-6 trial evaluating camizestrant, which uniquely enrolled patients with molecularly detected ESR1 ...
Some breast cancer survivors may have a slightly reduced risk for Alzheimer’s disease, though the benefit appears to be ...
Cite this: Cognitive Dysfunction in Postmenopausal Breast Cancer Patients on Aromatase Inhibitors - Medscape - Aug 01, 2011.
Panelists discuss the evolving management of estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer, ...
Repronovo announces first participant included in US phase 2 trial of RPN-001 to treat MALE INFERTILITY: Lausanne, Switzerland Wednesday, July 2, 2025, 14:00 Hrs [IST] ReproNovo, ...
In 2004, the American Society of Clinical Oncology reported its evaluation of the use of aromatase inhibitors (AIs) in the adjuvant treatment of postmenopausal breast cancer. While the panel endorsed ...
14d
India Today on MSNNew drug could transform treatment for advanced breast cancer in IndiaA new drug, camizestrant, shows promise in delaying progression of aggressive breast cancer. This treatment uses blood ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results